Orchard Therapeutics (NASDAQ:ORTX) Reaches New 52-Week Low at $5.07

Shares of Orchard Therapeutics PLC – (NASDAQ:ORTX) reached a new 52-week low during trading on Tuesday . The stock traded as low as $5.07 and last traded at $5.07, with a volume of 12049 shares trading hands. The stock had previously closed at $5.36.

Several research firms recently commented on ORTX. ValuEngine upgraded shares of Orchard Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday. BidaskClub downgraded shares of Orchard Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, June 11th. JPMorgan Chase & Co. cut their price objective on shares of Orchard Therapeutics from $26.00 to $17.00 and set an “overweight” rating for the company in a research report on Friday, May 22nd. Finally, Oppenheimer initiated coverage on shares of Orchard Therapeutics in a research report on Monday, June 1st. They set a “buy” rating for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Orchard Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $23.00.

The business’s fifty day moving average price is $7.33 and its 200 day moving average price is $10.22. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.66 and a quick ratio of 6.66. The stock has a market cap of $516.47 million, a P/E ratio of -2.81 and a beta of 1.07.

Orchard Therapeutics (NASDAQ:ORTX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.01). On average, analysts predict that Orchard Therapeutics PLC – will post -1.79 earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in ORTX. RA Capital Management L.P. increased its holdings in Orchard Therapeutics by 62.2% in the 1st quarter. RA Capital Management L.P. now owns 10,364,658 shares of the company’s stock worth $57,048,000 after acquiring an additional 3,974,757 shares during the last quarter. Vivo Capital LLC purchased a new stake in Orchard Therapeutics in the 1st quarter worth about $12,253,000. ArrowMark Colorado Holdings LLC increased its holdings in Orchard Therapeutics by 13.7% in the 1st quarter. ArrowMark Colorado Holdings LLC now owns 1,488,314 shares of the company’s stock worth $11,207,000 after acquiring an additional 179,717 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Orchard Therapeutics by 6,219.5% in the 1st quarter. Janus Henderson Group PLC now owns 978,887 shares of the company’s stock worth $7,371,000 after acquiring an additional 963,397 shares during the last quarter. Finally, Casdin Capital LLC increased its holdings in Orchard Therapeutics by 18.9% in the 1st quarter. Casdin Capital LLC now owns 975,000 shares of the company’s stock worth $7,342,000 after acquiring an additional 155,000 shares during the last quarter. 68.90% of the stock is owned by institutional investors.

About Orchard Therapeutics (NASDAQ:ORTX)

Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.

Recommended Story: The Structure of a Futures Contract

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.